Atazanavir-containing renal calculi in an HIV-infected patient.

摘要

Approximately 7% of an atazanavir (Reyataz; Bristol-Myers Squibb, Princeton, New jersey, USA) dose is (excreted as unchanged drug in the urine and the solubility of atazanavir increases with acidity . These properties are similar to those of indinavir, which is more soluble in acid solutions and of which 19% is excreted as unchanged drug in the urine. Indinavir is associated with precipitation in the urine and clinical sequelae in 4-43% of patients. Conversely, there have been only two recent case reports of atazanavir-associated urolithiasis in the literature. We report here another case of renal calculi containing significant amounts of atazanavir in an HIV-infected patient.